14
Views
1
CrossRef citations to date
0
Altmetric
Drug Profile

Adalimumab for the treatment of psoriasis

&
Pages 15-21 | Published online: 10 Jan 2014
 

Abstract

Psoriasis is a debilitating skin disorder that affects 2% of the Caucasian population. In those with moderate-to-severe disease, treatment is challenging, with many cases ultimately proving refractory to traditional systemic therapies, such as methotrexate. For this group of patients, biologic therapies have emerged as novel, targeted approaches for management. One of these, the anti-TNF-α inhibitor adalimumab, is the focus of this article, with emphasis on its pharmacology, clinical efficacy and safety profile.

Financial & competing interests disclosure

RB Warren has received speakers or consulting fees from Abbott, Janssen-Cilag and Schering-Plough. CEM Griffiths has acted as a paid consultant or lecturer or has received research funding from Abbott, Janssen-Cilag, Merck-Serono, Schering-Plough and Wyeth. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Log in via your institution

Log in to Taylor & Francis Online

PDF download + Online access
  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 99.00 Add to cart
* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.